Author Interviews, Cancer Research, Duke, Heart Disease, Pediatrics / 06.12.2022

MedicalResearch.com Interview with: [caption id="attachment_59798" align="alignleft" width="150"]Amy Berkman, MDDepartment of Pediatrics Duke University School of Medicine Dr. Berkman[/caption] Amy Berkman, MD Department of Pediatrics Duke University School of Medicine MedicalResearch.com: What is the background for this study? Response: Cancer incidence in adolescents and young adults (AYAs, aged 15-39 years at diagnosis) is increasing, with approximately 90,000 new diagnoses annually in the US. Improvements in 5-year survival have led to a growing population of survivors of AYA cancer, currently estimated at >600,000 survivors. Survivors are at increased risk of treatment related chronic conditions including cardiovascular disease (CVD). We wanted to determine whether certain sociodemographic and medical history factors further increase the risk of CVD in AYA cancer survivors and also compare risk of CVD between AYA cancer survivors and the general population.
Author Interviews, Cancer Research, Lung Cancer, NYU/NYMC / 14.11.2022

MedicalResearch.com Interview with: [caption id="attachment_59732" align="alignleft" width="150"]Dr. Sally Lau Dr. Sally Lau[/caption] Dr. Sally Lau MD Medical oncologist, NYU Langone’s Perlmutter Cancer Center Assistant professor of medicine NYU Grossman School of Medicine MedicalResearch.com: How big is the problem of lung cancer? Response: Amongst all cancer types, lung cancer is the number 1 killer in the US.
Author Interviews, Cancer Research, Colon Cancer, Genetic Research, Nature / 18.10.2022

MedicalResearch.com Interview with: [caption id="attachment_59644" align="alignleft" width="150"]Royce Zhou, MD/PhD Candidate Icahn School of Medicine at Mount Sinai Royce Zhou[/caption] Royce Zhou, MD/PhD Candidate Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? Response: The background of this story is to see whether things outside of the cancer cell, such as the tumor microenvironment, can lead to epigenetic changes within the cancer cell. These changes are largely believed to be due to factors inside the cell, not outside. Super-enhancers are the top 1-2% of enhancers in the genome. They control cell identity genes and oncogenes in cancer.
Author Interviews, Cancer Research, Dermatology, Melanoma / 22.09.2022

MedicalResearch.com Interview with: “Prof. Ronit Satchi-Fainaro, the Director of the Cancer Biology Research Center led this study with an outstanding PhD student, Sabina Pozzi” Prof. Ronit Satchi-Fainaro, Ph.D. Head, Cancer Research and Nanomedicine Laboratory Kurt and Herman Lion Chair in Nanosciences and Nanotechnologies Director, Cancer Biology Research Center Department of Physiology and Pharmacology Sackler Faculty of Medicine Sagol School of Neuroscience Tel Aviv University, Tel Aviv 69978, Israel MedicalResearch.com: What is the background for this study? Response: Cutaneous melanoma is the deadliest of all skin cancers, especially due to its tendency to invade and develop metastases with an incidence of brain metastasis development of 40% to 50% in patients with melanoma stage IV (although the incidence post mortem is 70–90%). We know that the brain microenvironment represents the first line of reaction in favor or against the tumor due to its dual ability to generate an immune-stimulatory or immunosuppressive niche, which will ultimately determine the establishment and growth of melanoma brain metastasis. Among the brain-resident cells, astrocytes are responsible for the maintenance of the brain homeostasis, and subsequent to melanoma brain colonization, they sustain and foster the growth of melanoma cells
Author Interviews, Cancer Research / 09.08.2022

MedicalResearch.com Interview with: [caption id="attachment_59424" align="alignleft" width="150"]Sarah S. Jackson PhD Infections and Immunoepidemiology Branch Division of Cancer Epidemiology and Genetics National Cancer Institute Bethesda, MD 20892 Dr. Jackson[/caption] Sarah S. Jackson PhD Infections and Immunoepidemiology Branch Division of Cancer Epidemiology and Genetics National Cancer Institute Bethesda, MD 20892 MedicalResearch.com: What is the background for this study? Response: There are many cancers that both men and women can develop, specifically those that do not affect the reproductive tract. Men have higher rates of these nonreproductive cancers than women. There are only two nonreproductive cancer types that are more common in women: thyroid and gallbladder. Historically, we have thought this is because women are less likely to smoke or drink and are more likely to eat well and exercise than men. This study sought to examine the sex bias in cancer incidence after controlling for those lifestyle factors to see if this explained the male predominance in cancer.
Author Interviews, Cancer Research, Nutrition / 26.07.2022

MedicalResearch.com Interview with: [caption id="attachment_59349" align="alignleft" width="135"]Prof. John C. Mathers PhD Director, Human Nutrition Research Centre Director, Centre for Healthier Lives Population Health Sciences Institute Newcastle University Newcastle on Tyne UK Prof. Mathers[/caption] Prof. John C. Mathers PhD Director, Human Nutrition Research Centre Director, Centre for Healthier Lives Population Health Sciences Institute Newcastle University Newcastle on Tyne UK MedicalResearch.com:  What is the background for this study?   Response: My colleagues and I have had a long-term interest in carrying out studies in people with hereditary cancer as a model for cancer in the general population. Here we studied people with Lynch syndrome who have an inherited defect in one of the genes encoding the DNA mismatch repair system. Because of this, they accumulate DNA damage faster than the general population and are prone to early cancers at several sites around the body. In the CAPP2 Study, we randomised almost 1000 people with Lynch syndrome to either resistant starch or to an ordinary corn-starch placebo.
Author Interviews, Cancer Research, JAMA, Race/Ethnic Diversity / 10.06.2022

MedicalResearch.com Interview with: [caption id="attachment_59246" align="alignleft" width="150"]Marquita W. Lewis-Thames Dr. Lewis-Thames[/caption] Marquita W. Lewis-Thames, PhD (she/her/Dr.) Assistant Professor, Department of Medical Social Science Center for Community Health, Member Researcher Assistant Directors of Community Outreach and Engagement, Robert H. Lurie Comprehensive Cancer Center Feinberg School of Medicine, Northwestern University MedicalResearch.com:  What is the background for this study?  What are the main findings?  Response: Incidence, mortality, and survivorship provide a comprehensive description of cancer for a group of people. Differences in cancer incidence and mortality trends by rural-urban status and race and ethnicity are well documented, but urban-rural cancer survivorship trends by race and ethnicity are unknown. To this end, we examined almost 40 years of racial and ethnic differences by rural-urban status for 5-year survival of patients with lung, prostate, breast, and colorectal cancers. Using a nationwide epidemiological assessment of 1975-2011 data from the SEER database, we found that 5-year cancer-specific survival trends increased for all cancer types and race and ethnic groups, regardless of rural or urban status. Generally, rural, and non-Hispanic Black cancer patients had worse survival outcomes than others.
ASCO, Author Interviews, Cancer Research, COVID -19 Coronavirus, NYU/NYMC / 08.06.2022

MedicalResearch.com Interview with: Katherine Garcia MD NYU Langone Health MedicalResearch.com:  What is the background for this study?  Response: Studies on cancer patients during the COVID-19 pandemic have shown a decrease in new diagnoses, delays in care, and a shift to later stage disease presentations. Considering that NY has been an epicenter for COVID-19 in the U.S., we investigated its impact on new cancer diagnoses at the two campuses of NYU’s Perlmutter Cancer Center and hypothesized that there would be a decrease in presentations during the peak outbreaks in NY.
Author Interviews, Cancer Research, Nature, Pancreatic, University of Michigan / 03.06.2022

MedicalResearch.com Interview with: [caption id="attachment_59198" align="alignleft" width="200"]Imad Shureiqi, MD, MS Professor, Division of Hematology and Oncology Department of Internal Medicine  Rogel Cancer Center Ann Arbor, MI, 48109 Prof. Shureiqi[/caption] Imad Shureiqi, MD, MS Professor, Division of Hematology and Oncology Department of Internal Medicine Rogel Cancer Center Ann Arbor, MI, 48109 MedicalResearch.com:  What is the background for this study?   Response: Pancreatic ductal adenocarcinoma is a highly lethal form of cancer with rising occurrence, and strategies to prevent and treat the disease are urgently needed. Most cases of pancreatic cancer arise from pre-cancerous lesions called pancreatic intraepithelial neoplasia (PanIN); about 55-80% of adults over forty are estimated to have these low-grade pre-cancerous silent pancreatic lesions. But critical factors that promote the progression of pancreatic pre-cancerous lesions to pancreatic cancer remain poorly defined, especially those easy to target. Findings from this publication indicate that people who have silent PanIN pre-cancerous lesions, even those that are low-grade, could increase their risk of PanIN progression into pancreatic cancer by consuming activators of a nuclear lipid receptor called peroxisome proliferator-activated receptor-delta (PPARδ). PPARδ activators can be natural substances, such certain fatty acids like palmitic and arachidonic acid in high-fat diets, or synthetic ones, like Cardarine (GW501516).
Author Interviews, Cancer Research, Gastrointestinal Disease / 20.05.2022

MedicalResearch.com Interview with: [caption id="attachment_59182" align="alignleft" width="150"]Bashar J. Qumseya, MD, MPH, FASGE Associate Professor of Medicine Chief of Endoscopy University of Florida, Gainesville  Dr. Qumseya[/caption] Bashar J. Qumseya, MD, MPH, FASGE Associate Professor of Medicine Chief of Endoscopy University of Florida, Gainesville  MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: Barrett’s esophagus (BE), is a premalignant condition that can lead to esophageal cancer (called esophageal adenocarcinoma). Both diseases have historically been thought of as diseases of elderly white males. While both diseases have been on the rise in the elderly population, we noted that some cancers are becoming more common at younger ages. We wanted to see if the prevalence of BE and EC are increasing at younger ages.  We aimed to assess the prevalence of BE in and EAC based on age group in a large database of over 5 million patients. 
Author Interviews, Biomarkers, Cancer Research, Colon Cancer / 18.05.2022

MedicalResearch.com Interview with: [caption id="attachment_59158" align="alignleft" width="150"]https://guardanthealth.com/ Dr. Talasaz[/caption] AmirAli Talasaz Ph.D. co-CEO, Guardant Health MedicalResearch.com:  What is the background for this announcement? Response: On May 2, Guardant Health announced the availability of Shield™, our first blood-based test for the detection of early-stage colorectal cancer (CRC). Colorectal cancer is the second-leading cause of cancer deaths in the U.S., so this announcement represents a tremendous public health opportunity. Here’s why: This new test will help people identify more CRC at its earliest stages, when it is most treatable. It offers an accurate, easy-to-complete, blood-based approach to CRC screening. It can be completed with a convenient blood draw during any healthcare provider visit. 
Author Interviews, Cancer Research, JAMA, NIH, Race/Ethnic Diversity / 05.05.2022

MedicalResearch.com Interview with: [caption id="attachment_59128" align="alignleft" width="125"]Megan Clarke, Ph.D., M.H.S., Earl Stadtman Investigator Division of Cancer Epidemiology and Genetics National Cancer Institute Dr. Clarke[/caption] Megan Clarke, Ph.D., M.H.S., Earl Stadtman Investigator Division of Cancer Epidemiology and Genetics National Cancer Institute MedicalResearch.com:  What is the background for this study? 
  • Through our prior work, we have demonstrated that uterine cancer incidence rates have been significantly increasing in the U.S. from 2003 to 2015 and that these increases were primarily driven by rising rates of aggressive (non-endometrioid) subtypes of this cancer. We observed that rates of these aggressive cancers increased among all women and were more than twice as high among Non-Hispanic Black women compared to other racial and ethnic groups. Factors explaining these trends, as well as the disproportionately higher rates of these aggressive subtypes among non-Hispanic Black women, remain unclear, in part because risk factors are poorly understood.
  • In addition to differences in incidence rates by race and ethnicity, we have also observed strong disparities in our prior studies, with Non-Hispanic Black women having substantially lower 5-year survival, regardless of subtype or stage at diagnosis, compared to other racial and ethnic populations.
  • The next logical step, and the focus of the current study, was to evaluate how increases in the incidence of aggressive, non-endometrioid uterine cancer affects racial disparities and rates of death from uterine cancer.
Author Interviews, Cancer Research, JAMA, Race/Ethnic Diversity, Radiology / 27.04.2022

MedicalResearch.com Interview with: [caption id="attachment_59092" align="alignleft" width="200"]Leticia Nogueira, PhD, MPH Senior Principal Scientist, Health Services Research American Cancer Society, Inc. Kennesaw, GA 30144 Dr. Nogueira[/caption] Leticia Nogueira, PhD, MPH Senior Principal Scientist, Health Services Research American Cancer Society, Inc. Kennesaw, GA 30144 MedicalResearch.com:  What is the background for this study?  Response: Proton Beam Therapy (PBT) can deliver higher dose of radiation to the tumor with less damage to surrounding healthy cells. Therefore, PBT is potentially superior to photon-based radiation therapy to treat tumors with complex anatomy, surrounded by sensitive tissues, or for treating childhood cancer (where long-term side effects of radiation therapy are a main concern). However, PBT can cost twice as much as photon-based radiation therapy. 
AACR, Author Interviews, Brigham & Women's - Harvard, Cancer Research / 18.04.2022

MedicalResearch.com Interview with: [caption id="attachment_59050" align="alignleft" width="150"]Ajit Johnson Nirmal PhD Instructor of Medicine, DFCI, HMS Laboratory of systems pharmacology Harvard Medical School Dr. Nirmal[/caption] Ajit Johnson Nirmal PhD Instructor of Medicine, DFCI, HMS Laboratory of systems pharmacology Harvard Medical School MedicalResearch.com:  What is the background for this study?  Response: Like many other types of cancers, melanoma arises from gene mutations within cells that impact cell growth and division. These abnormal cells should be rapidly eliminated by our immune system, however, the failure to do so leads to the development of cancer. Hence researchers have long been interested to study the tumor environment that nurtures and sustains these dangerous cells. In the past, researchers have used single-cell technologies to delineate the cell types and cell states that make up the tumor microenvironment. However, the spatial relationships between these cell types and how they organize themselves such as to provide a favorable environment for the tumor to develop remains unknown. In the last couple of years, researchers have developed a new suite of new technologies called spatial omics which includes CYCIF a method that was developed at Sorger lab. Using this method, we can not only measure the molecular information of cells at a single cell level but also their spatial context. This allows us to build a google map like view of the skin with melanoma and study what is exactly happening that allows the tumors to develop.
Author Interviews, Cancer Research, Clots - Coagulation / 18.04.2022

MedicalResearch.com Interview with: [caption id="attachment_59045" align="alignleft" width="150"]Dr. med. univ. Cornelia Englisch Medical University of Vienna Dr. Englisch[/caption] Dr. med. univ. Cornelia Englisch Medical University of Vienna MedicalResearch.com:  What is the background for this study?  Response: Patients with cancer are at high risk for developing venous thromboembolism (VTE). Venous thromboembolism includes deep vein thrombosis (DVT), when blood clots form in the deep veins of the legs and pulmonary embolism (PE), a potential life-threatening condition when a clot breaks free and lodges in the arteries of the lung. Having a non-O blood type, meaning blood types A, AB or B, is a known risk factor for VTE in the general – non-cancer – population. Interestingly, it is the most common genetic risk factor for thrombosis. If this is also the case in patients with cancer has not been clarified yet. We therefore wanted to assess the role of ABO blood type in cancer-associated thrombosis. To achieve our goal, we utilized the dataset of the Vienna Cancer and Thrombosis Study (CATS); an observational cohort study including adult patients with active cancer.
Author Interviews, Cancer Research, Nutrition, Supplements / 06.01.2022

MedicalResearch.com Interview with: Dr Rana Conway PhD RNutr  Research Fellow Energy Balance & Cancer Group, and Obesity Research Group Research Department of Behavioural Science and Health University College London    MedicalResearch.com: What is the background for this study? Response: We’ve seen great advances in cancer diagnosis and treatment in recent years which means the number of people living with and beyond a cancer diagnosis is rapidly increasing. The WCRF and CRUK recommend improving diet and exercise to reduce the risks of cancer coming back but we know anecdotally that supplements are sometimes seen as an easier option, and people who’ve had cancer are often interested to know if they should be taking any supplements.   
Author Interviews, Cancer Research, HPV / 17.12.2021

MedicalResearch.com Interview with: [caption id="attachment_58558" align="alignleft" width="176"]Ashish A. Deshmukh, PhD, MPH Associate Professor, Management, Policy & Community Health Associate Director, Center for Health Services Research Co-director, Clinical Analytics and Decision Science Lab UTHealth School of Public Health Houston, TX 77030 Dr. Deshmukh[/caption] Ashish A. Deshmukh, PhD, MPH Associate Professor, Management, Policy & Community Health Associate Director, Center for Health Services Research Co-director, Clinical Analytics and Decision Science Lab UTHealth School of Public Health Houston, TX 77030 MedicalResearch.com: What is the background for this study? Response: Oropharyngeal cancer is the most common cancer caused by human papillomavirus (HPV) in the United States (US). We know from previous studies that oropharyngeal cancer to be one of the fastest rising cancers in the US. However, trends (i.e., extent of change) in incidence rates among men and women in all 50 US states and trends according to tumor diagnostic characteristics (i.e., stage, size) have not been comprehensively studied. In addition, no prior study evaluated contemporary trends in oropharyngeal cancer mortality (death) rates in the US. Our study provides a comprehensive picture of oropharyngeal cancer incidence and mortality (according to age, stage, tumor size, and state of residence) in all 50 states and DC.
Author Interviews, Cancer Research / 27.10.2021

MedicalResearch.com Interview with: [caption id="attachment_58316" align="alignleft" width="200"]Shoshana Rosenzweig Medical Student at the Icahn School of Medicine at Mount Sinai Shoshana Rosenzweig[/caption] Shoshana Rosenzweig Medical Student Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? Would you briefly describe the Phantosmia phenomenon?  Response: Phantosmia is an olfactive disorder resulting in the perception of a foul-smelling odor without odorant stimulus. This study was spearheaded by Dr. Suzanne Wolden, a pediatric radiation oncologist and the senior author of the research. She noticed that patients receiving proton beam therapy were complaining of this phenomenon more than her patients receiving photon therapy. Through this research, the team hoped to characterize radiation treatment induced phantosmia in pediatric, adolescent and young adult patients treated with proton beam therapy and we hoped to identify potential clinical and treatment-related characteristics that may correlate with the development of phantosmia. 
Author Interviews, Brigham & Women's - Harvard, Cancer Research, Cost of Health Care, JAMA / 20.10.2021

MedicalResearch.com Interview with: [caption id="attachment_58259" align="alignleft" width="200"]Anita Katharina Wagner, PharmD, MPH, DrPH Associate Professor of Population Medicine Director, Ethics Program, Point32Health (parent company of Harvard Pilgrim Health Care and Tufts Health Plan) Co-Director, HMS Fellowship in Health Policy and Insurance Research Co-Director, Center for Cancer Policy and Program Evaluation (CarPE) Department of Population Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute Dr. Wagner[/caption] Anita Katharina Wagner, PharmD, MPH, DrPH Associate Professor of Population Medicine Director, Ethics Program, Point32Health (parent company of Harvard Pilgrim Health Care and Tufts Health Plan) Co-Director, HMS Fellowship in Health Policy and Insurance Research Co-Director, Center for Cancer Policy and Program Evaluation (CarPE) Department of Population Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute MedicalResearch.com: What is the background for this study? What are the main findings? Response: The expectation for new cancer drugs is that they help patients live better longer. Increasingly more cancer drugs are approved without documented quality of life or overall survival benefits.   At the same time, cancer drug prices are rising.  We studied use of and spending on selected new cancer drugs among patients with employer-sponsored health insurance. We found that among 37348 patients who received one or more of 44 oral targeted cancer drugs, the proportion of patients who received a drug without documented overall survival benefit increased from 13% in 2011 to 59% in 2018.  By 2018, spending on drugs without documented overall survival benefit accounted for 52% of the $3.5 million spend on the 44 drugs since 2011.
Aging, Author Interviews, Cancer Research, Dermatology, Frailty, JAMA / 08.09.2021

MedicalResearch.com Interview with: [caption id="attachment_58071" align="alignleft" width="225"] Dr. van Winden[/caption] Marieke van Winden MD MSc PhD candidate Dermatology Radboud Institute for Health Sciences Department of Dermatology Radboud University Medical Center Nijmegen, the Netherlands MedicalResearch.com: What is the background for this study? What underlying conditions would factor in a decision for Watchful Waiting?  Response: Basal cell carcinomas are frequently treated because of the risk for progression, which can cause a significant morbidity due to local tissue invasion and destruction. However, most BCCs are characterized by a relatively indolent nature, growing slowly and frequently asymptomatically. Because patients with a limited life expectancy might not live long enough to develop symptoms from basal cell carcinoma progression, they might not live long enough to benefit from treatment. Underlying conditions that determine life expectancy should therefore be considered when weighing BCC management options. When life expectancy is expected to be relatively short, and the consequences of  watchful waiting (WW) are relatively low risk (low tumor burden expected within the remaining lifespan), WW should be considered.
Author Interviews, Cancer Research, Colon Cancer / 02.09.2021

MedicalResearch.com Interview with: [caption id="attachment_58026" align="alignleft" width="200"]Sophia Harlid, Ph.D. Associate Professor/Docent in Molecular Epidemiology Department of Radiation Sciences Umeå University Umeå, Sweden Dr. Harlid[/caption] Sophia Harlid, Ph.D. Associate Professor/Docent in Molecular Epidemiology Department of Radiation Sciences Umeå University Umeå, Sweden MedicalResearch.com: What is the background for this study? Response: Antibiotics has previously been associated with in increased risk of colorectal cancer, with this study we were able to use comprehensive registry data to further break down and validate this relationship. 
Author Interviews, Exercise - Fitness, JAMA, Prostate Cancer / 24.08.2021

MedicalResearch.com Interview with: [caption id="attachment_57975" align="alignleft" width="200"]Kerry S. Courneya, PhD Professor and Canada Research Chair in Physical Activity and Cancer Director, Behavioral Medicine Laboratory and Fitness Center Faculty of Kinesiology, Sport, and Recreation | College of Health Sciences University of Alberta | Edmonton, Alberta | CANADA Dr. Courneya[/caption] Kerry S. Courneya, PhD Professor and Canada Research Chair in Physical Activity and Cancer Director, Behavioral Medicine Laboratory and Fitness Center Faculty of Kinesiology, Sport, and Recreation | College of Health Sciences University of Alberta | Edmonton, Alberta | CANADA  MedicalResearch.com: What is the background for this study? Response: An increasing number of men with low risk prostate cancer (PCa) do not receive any immediate medical treatments for their PCa. This practice is called active surveillance (AS). It can be very stressful for men because about one-third of them will eventually experience disease progression and require medical treatments. Right now, there is nothing these men can really do for themselves other than to attend all of their follow-up medical visits. Some research has shown that exercise may slow the progression of prostate tumours and metastasis in animal models and improve quality of life in men during and after PCa treatments. Very little research, however, has been conducted in the AS setting. We wanted to see if a high intensity interval training exercise program could improve fitness and prevent or delay biochemical progression of PCa in the AS setting.
Author Interviews, Cancer Research, Gastrointestinal Disease, Science / 13.08.2021

MedicalResearch.com Interview with: Dr Lizhe Zhuang PhD Dr Karol Nowicki-Osuch PhD Dr. Rebecca C. Fitzgerald MD Medical Research Council Cancer Unit, Hutchison/Medical Research Council Research Centre, University of Cambridge, Cambridge UK [caption id="attachment_43740" align="alignleft" width="200"]Barrett's Esophagus -wikipedia Barrett's Esophagus -Wikipedia[/caption] MedicalResearch.com: What is the background for this study? Barrett’s oesophagus affects about one out of 100 people in the UK and is thought to be a precancerous lesion of a more deadline cancer, oesophageal adenocarcinoma. Barrett’s is a condition where the squamous cells in the lower part of oesophagus are replaced by a special type of columnar cells, which look like intestine, a far distant organ, raising a question where are these columnar cells come from. Many theories have been proposed in the past decades and no agreement was reached, and many conclusions were based on mouse models which do not recap the human condition. We therefore collected fresh samples of human tissues that correspond to all the possible theories and assessed them all together using state of the art technologies. 
Author Interviews, Cancer Research, CDC, Emory, Gender Differences, Race/Ethnic Diversity / 08.07.2021

MedicalResearch.com Interview with: [caption id="attachment_57756" align="alignleft" width="200"]Farhad Islami, MD PHD  Scientific Director, Cancer Disparity Research American Cancer Society Dr. Islami[/caption] Farhad Islami, MD PHD Scientific Director, Cancer Disparity Research American Cancer Society MedicalResearch.com: What is the background for this study? Response: The Centers for Disease Control and Prevention (CDC), the American Cancer Society (ACS), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) have collaborated annually since 1998 to provide updated information about cancer occurrence and trends by cancer type, sex, age group, and racial/ethnic group in the United States. In this year’s report, we focus on national cancer statistics and highlight trends in stage-specific survival for melanoma of the skin, the first cancer for which effective immune checkpoint inhibitors were developed.
ASCO, Author Interviews, Cancer Research / 07.06.2021

MedicalResearch.com Interview with: [caption id="attachment_57555" align="alignleft" width="200"]Mai Takahashi MD MPH Mount Sinai Beth Israel - Resident Physician New York, New York Dr. Takahashi[/caption] Mai Takahashi MD MPH Mount Sinai Beth Israel - Resident Physician New York, New York MedicalResearch.com: What is the background for this study? Response: The incidence of head and neck cancer had been significantly increasing in North America and Europe driven by Human Papillomavirus-related cancer (HPV OPC) which account for more than 60% of total oropharyngeal cancer cases. Compared to environmentally related oropharyngeal cancer, the HPV OPC patient population is generally younger and has a much better prognosis. However, they will suffer from long-term deteriorations in quality of life (QoL) and the declines associated with treatment intensity. Hence multiple studies have focused on de-intensification therapy with reduced dose chemoradiotherapy (CRT). 
Author Interviews, Brigham & Women's - Harvard, Journal Clinical Oncology, Prostate Cancer, Radiation Therapy / 04.06.2021

MedicalResearch.com Interview with: [caption id="attachment_57600" align="alignleft" width="200"]Dr. D'Amico Dr. D'Amico[/caption] Anthony D'Amico, MD, PhD Professor and Chief of Genitourinary Radiation Oncology Brigham and Women's Hospital and Dana-Farber Cancer Institute MedicalResearch.com: What is the background for this study? Response: 3 randomized trials published in Sept, 2020 in the Lancet and Lancet Oncology concluded that delivering radiation therapy (RT) after surgery for prostate cancer   when the PSA rises signaling recurrence (i.e. early salvage RT) as opposed to when the PSA is undetectable (i.e. adjuvant RT) did not compromise subsequent cancer progression. However these trials may have missed the benefit of adjuvant RT because a minority of men (9 to 17% of the study cohorts) were found to have adverse factors at prostatectomy which are associated with cancer progression and death from prostate cancer. Specifically, men with adverse pathology at prostatectomy comprise the vast majority of men who go on to die from prostate cancer and therefore have the most to gain from adjuvant RT. Yet, given the results of the 3 randomized trials many physicians are no longer offering adjuvant RT, even in men with adverse pathology at surgery.
Author Interviews, Breast Cancer, Cancer Research, Radiation Therapy / 03.06.2021

  [caption id="attachment_57547" align="alignleft" width="400"]Prof Jeffrey S Tobias, Prof Jayant S Vaidya, Prof Max Bulsara and Prof Michael Baum Prof Jeffrey S Tobias, Prof Jayant S Vaidya, Prof Max Bulsara and Prof Michael BaumMedicalResearch.com Interview with:[/caption] Professor Jayant S Vaidya MBBS MS DNB FRCS PhD Professor of Surgery and Oncology University College London MedicalResearch.com: What is the background for this study? What type of single dose radiation is used? Response: The new paper published in the British Journal of Cancer (go.nature.com/3yN0mzu) expands on the previously published results of the large international randomised trial (TARGIT-A trial)(BMJ 2020;370:m2836), that confirmed the long-term effectiveness of Targeted Intraoperative Radiotherapy (TARGIT-IORT): a breast cancer treatment which is increasingly available throughout the world. The TARGIT-A trial found that a single dose of targeted radiotherapy during surgery (TARGIT-IORT) is just as effective as conventional radiotherapy, which requires several visits to hospital after surgery. From the perspective of patients, it is so much better for them and also allows prompt completion of cancer treatment during the COVID pandemic. Conventional external beam radiotherapy (EBRT) is delivered from outside the body via a radiotherapy machine (linear accelerator), and consists of a daily treatment session (known as fractions) to the whole breast, over a period between three to six weeks. Each of these treatments is given over a few minutes, but requires up to 30 hospital visits, which could be a significant distance from where the patient lives. TARGIT-IORT is delivered immediately after lumpectomy (tumour removal), via a small ball-shaped device placed inside the breast, directly where the cancer had been. The single-dose treatment lasts for around 20 to 30 minutes and replaces the need for extra hospital visits, benefiting both patient safety and well-being. The device used is called INTRABEAM. The new results are described on the Nature.com and UCL webpages https://www.ucl.ac.uk/news/2021/may/pioneering-single-dose-radiotherapy-breast-cancer-treatment and explained in a short video https://youtu.be/w0OMjVfJ5pY 
Author Interviews, Lipids, Prostate Cancer / 03.06.2021

MedicalResearch.com Interview with: [caption id="attachment_57541" align="alignleft" width="200"]Michelle Hill, PhD  Head, Precision & Systems Biomedicine Group QIMR Berghofer Medical Research Institute Dr. Michele Hill[/caption] Michelle Hill, PhD Head, Precision & Systems Biomedicine Group QIMR Berghofer Medical Research Institute MedicalResearch.com: What is the background for this study? Response: The role of cholesterol and cholesterol lowering drug therapy in prostate cancer has been previously investigated with mixed results. Our previous laboratory studies indicate that high cholesterol diet accelerates the spreading of advanced prostate cancer. We also observed a change of the cellular location of cholesterol, from the cell periphery (plasma membrane) to inside the cell. This study investigates the how the change in cholesterol location promotes prostate cancer spread.
Author Interviews, Cancer Research, Colon Cancer, JAMA, USPSTF / 26.05.2021

MedicalResearch.com Interview with: [caption id="attachment_57486" align="alignleft" width="133"]Martha Kubik, Ph.D., R.N. Professor and Director School of Nursing College of Health and Human Services George Mason University Dr. Kubik[/caption] Martha Kubik, Ph.D., R.N. Professor and Director School of Nursing College of Health and Human Services George Mason University MedicalResearch.com: What is the background for this study? Response: Colorectal cancer is the third leading cause of cancer deaths in the United States, yet about a quarter of people ages 50 to 75 have never been screened for this devastating disease. Fortunately, we know that screening for colorectal cancer is effective and saves lives. New science about colorectal cancer in people younger than 50 years old has enabled us to expand our previous guidelines to recommend that all adults ages 45 to 75 be screened for colorectal cancer to reduce their risk of dying from this disease.